Search alternatives:
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 141 - 160 results of 108,864 for search '(( 4 w decrease ) OR ( 5 ((((wt decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.66s Refine Results
  1. 141
    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression.

    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. by Xiaojuan Li (351842)

    Published 2023
    Save to List
    Saved in:
  2. 142
    CD148 knockdown reduces cell-cell adhesion and E-cadherin contacts accompanied by a decrease in Rac1 activity in A431 cells.

    CD148 knockdown reduces cell-cell adhesion and E-cadherin contacts accompanied by a decrease in Rac1 activity in A431 cells. by Keiko Takahashi (375228)

    Published 2014
    “…CD148 knockdown reduces the E-cadherin contact formation accompanied by a decrease in Rac1 activity.</p>…”
    Save to List
    Saved in:
  3. 143
    Lack of TLR signaling (MyD88<sup>-/-</sup>) results in decreased levels of cytokines in the cornea.

    Lack of TLR signaling (MyD88<sup>-/-</sup>) results in decreased levels of cytokines in the cornea. by Rose Y. Reins (2586106)

    Published 2017
    Save to List
    Saved in:
  4. 144
    SPL treatment decreases diabetes-induced co-immunoprecipitation (co-IP) of cldn-4 and -8.

    SPL treatment decreases diabetes-induced co-immunoprecipitation (co-IP) of cldn-4 and -8. by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…Also, increased co-IP of cldn-8 with cldn-4 was found under diabetic condition and SPL decreased this interaction (C), densitometric analysis show that these changes were significant (D) (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s005" target="_blank">S5 Fig</a>). …”
    Save to List
    Saved in:
  5. 145
    (R)-albuterol decreases cytokine mRNA levels in activated T cells

    (R)-albuterol decreases cytokine mRNA levels in activated T cells by Marcela A Ferrada (41716)

    Published 2011
    “…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”
    Save to List
    Saved in:
  6. 146
    Decreased numbers of motor neurons in Tc1 and Dp(16)1Yey mice.

    Decreased numbers of motor neurons in Tc1 and Dp(16)1Yey mice. by Sheona Watson-Scales (586942)

    Published 2018
    Save to List
    Saved in:
  7. 147
    Cerebral edema and clinical signs of CM are decreased in α<sub>D</sub> <sup>-/-</sup> mice infected with <i>P</i>. <i>berghei</i> ANKA.

    Cerebral edema and clinical signs of CM are decreased in α<sub>D</sub> <sup>-/-</sup> mice infected with <i>P</i>. <i>berghei</i> ANKA. by Isaclaudia G. de Azevedo-Quintanilha (8173734)

    Published 2019
    Save to List
    Saved in:
  8. 148
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 149
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 150
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 151
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 152
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 153
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 154
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 155
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 156
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 157
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 158
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 159
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 160
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: